References
- 1. Poon MC, Di Minno G, d'Oiron R, Zotz R. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev 2016; 30(2): 92-9.10.1016/j.tmrv.2016.01.001
- 2. Engelen ET, van Galen KP, Schutgens RE. Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. Haemophilia 2015;21(4): 419-29.
- 3. Sami SS, Al-Araji SA, Ragunath K. Review article: gastrointestinal angiodysplasia - pathogenesis, diagnosis and management. Aliment Pharmacol Ther 2014; 39(1): 15-34.
- 4. Alikhan R, Keeling D. Von Willebrand disease, angiodysplasia and atorvastatin. Br J Haematol 2010;149(1): 159-60.
- 5. Leebeek FWG, Mauser-Bunschoten EP, Utrecht. Dutch guidelines for diagnosis and treatment of hemophilia and other rare bleeding disorders. ISBN 987-90-8253-195-0. 2009.
- 1. Solh T, Botsford A, Solh M. Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med 2015; 6: 219-27.
- 2. Bauditz J. Effective treatment of gastrointestinal bleeding with thalidomide - chances and limitations. World J Gastroenterol 2016; 22(11): 3158-64.10.3748/wjg.v22.i11.3158
- 3. Sohal M, Laffan M. Von Willebrand disease and angiodysplasia responding to atorvastatin. Br J Haematol 2008; 142(2): 308-9.
- 4. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology, 9th edn. Philadelphia, PA: Elsevier Saunders; 2012.